TD Cowen maintains Hold rating on Moderna, $90 price target
TD Cowen kept its Hold rating on Moderna (MRNA) with a $90 price target, implying a 62.8% downside from the Oct 20 close. The firm cited positive clinical developments and resilient revenue projections for Moderna's COVID-19 and INT franchises.
How this was made
The 30-second read
Why it matters
The new target signals a sharp downside, likely prompting short‑term selling pressure.
Market read
Analyst price‑target revision is a primary catalyst for Moderna's stock movement today.
What to watch
Potential upside from upcoming INT franchise collaborations and resilient COVID‑19 revenue stream.
Background
TD Cowen's analyst note reiterates a Hold rating and sets a $90 price target for Moderna, highlighting recent clinical progress and revenue outlook.
Ticker impact
TD Cowen maintains Hold rating on Moderna with a new $90 price target, implying a 62.8% downside from the recent close.
likely pressure as investors price in the steep downside from the $90 target
Analyst downgrade to a $90 target is a fresh catalyst that could trigger sell‑offs.
Market effects
Biotech sector may see modest pullback as a major mRNA player receives a lower target.
U.S. biotech stocks could experience slight weakness.
Limited to investors tracking Moderna and related vaccine/therapeutics pipelines.
Counterpoint
Some investors may view the lower target as an overreaction and see buying opportunity at current levels.
Key entities
- companyModerna
Biotech firm developing mRNA therapeutics and vaccines.
- analyst_firmTD Cowen
Equity research firm providing the rating and target.
